Rossari Biotech Ltd (ROSSARI) Price & Analysis

Compare

2 Followers

ROSSARI Stock Chart & Stats

₹583.95

₹39.25(5.10%)

At close: Jan 08 4:00 PM EST

₹583.95

₹39.25(5.10%)

Day’s Range― - ―

52-Week Range₹503.85 - ₹767.55

Previous CloseN/A

Volume112.05K

Average Volume (3M)2.66K

Market Cap

₹28.66B

Enterprise Value₹31.26B

Total Cash (Recent Filing)₹1.17B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)20.8

Beta0.87

Next Earnings

Apr 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.09%

Share Statistics

EPS (TTM)5.90

Shares Outstanding55,383,366

10 Day Avg. Volume1,386

30 Day Avg. Volume2,661

Financial Highlights & Ratios

PEG Ratio5.98

Price to Book (P/B)2.88

Price to Sales (P/S)1.64

P/FCF Ratio-161.88

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Consistent Revenue And Margin ImprovementSustained revenue growth coupled with higher gross and EBIT margins indicates durable demand for higher-value speciality formulations and improving operational efficiency. Over months, stronger margins support reinvestment, pricing power and resilience versus commodity peers, underpinning long-term profit quality.

Low Leverage And Solid Equity BaseVery low debt and a high equity ratio provide financial flexibility to fund expansion and absorb demand shocks without heavy interest burden. Improved ROE shows capital is being used more effectively; this balance-sheet strength supports durable investment capacity and lower refinancing risk.

Diversified B2B Product And End-market MixA multi-end-market, B2B product mix and emphasis on custom formulations create repeated commercial relationships and reduce single-market dependency. Structural diversification across textiles, H&PC and industrial uses smooths revenue cycles and supports sustained demand for specialty offerings over months.

Bears Say

Negative Free Cash Flow Due To CapexPersistent negative free cash flow from elevated capital spending can erode liquidity and limit self-funded growth. Over a multi-month horizon, continuing high capex versus operating cash generation may force external financing, constrain working capital, or delay returns to shareholders.

Pressure On Operational Cash Generation (EBITDA)A declining EBITDA margin signals narrowing operational cash conversion and potential cost or mix pressures. If sustained, it reduces internal funds for R&D and capex, weakens buffer against raw material swings, and could hamper long-term investment and margin sustainability.

Exposure To Cyclical End-marketsSubstantial revenue sensitivity to textile processing volumes and FMCG demand introduces cyclical risk. Structural swings in end-market activity or raw-material-driven margin compression can materially affect revenues and margins over months, challenging predictability of cash flows.

Rossari Biotech Ltd News

Rossari Biotech Publishes Extract of Q3 FY26 Consolidated Unaudited Results in Newspapers

Rossari Biotech Ltd ( ($IN:ROSSARI) ) has issued an announcement. Rossari Biotech Ltd has notified the stock exchanges...

1M ago

Rossari Biotech Releases Q3 and 9-Month FY26 Earnings Presentation

An update from Rossari Biotech Ltd ( ($IN:ROSSARI) ) is now available. Rossari Biotech Limited has released its...

1M ago

Rossari Biotech Delivers Double-Digit Revenue Growth in Q3 FY26 Amid Margin Pressure

Rossari Biotech Ltd ( ($IN:ROSSARI) ) has shared an announcement. Rossari Biotech reported a solid set of numbers...

1M ago

Rossari Biotech’s Credit Rating Reaffirmed by ICRA

Rossari Biotech Ltd ( ($IN:ROSSARI) ) has provided an update. Rossari Biotech Ltd has announced that ICRA Limited...

3M ago

Rossari Biotech Subsidiary Secures Leasehold Land in Gujarat

An announcement from Rossari Biotech Ltd ( ($IN:ROSSARI) ) is now available. Rossari Biotech Ltd announced that its...

3M ago

Rossari Biotech Affirms Regulatory Compliance for Q3 2025

The latest announcement is out from Rossari Biotech Ltd ( ($IN:ROSSARI) ). Rossari Biotech Ltd has released a...

5M ago

Rossari Biotech Announces Trading Window Closure Ahead of Financial Results

An update from Rossari Biotech Ltd ( ($IN:ROSSARI) ) is now available. Rossari Biotech Ltd has announced the...

5M ago

Rossari Biotech to Engage with Investors and Analysts in Upcoming Meeting

The latest update is out from Rossari Biotech Ltd ( ($IN:ROSSARI) ). Rossari Biotech Ltd has announced its...

5M ago

Rossari Biotech Ltd Holds Successful 16th AGM, Secures Shareholder Approval for Key Resolutions

Rossari Biotech Ltd ( ($IN:ROSSARI) ) has shared an announcement. Rossari Biotech Ltd successfully conducted its 16th Annual...

8M ago

Rossari Biotech Releases Q4 & FY25 Earnings Presentation

Rossari Biotech Ltd ( ($IN:ROSSARI) ) just unveiled an update. Rossari Biotech Limited has released its earnings presentation...

10M ago

ROSSARI FAQ

What was Rossari Biotech Ltd’s price range in the past 12 months?

Rossari Biotech Ltd lowest stock price was ₹503.85 and its highest was ₹767.55 in the past 12 months.

What is Rossari Biotech Ltd’s market cap?

Rossari Biotech Ltd’s market cap is ₹28.66B.

When is Rossari Biotech Ltd’s upcoming earnings report date?

Rossari Biotech Ltd’s upcoming earnings report date is Apr 27, 2026 which is in 64 days.

How were Rossari Biotech Ltd’s earnings last quarter?

Rossari Biotech Ltd released its earnings results on Jan 17, 2026. The company reported ₹5.9 earnings per share for the quarter, missing the consensus estimate of ₹6.2 by -₹0.3.

Is Rossari Biotech Ltd overvalued?

According to Wall Street analysts Rossari Biotech Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Rossari Biotech Ltd pay dividends?

Rossari Biotech Ltd pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.09%. See more information on Rossari Biotech Ltd dividends here

What is Rossari Biotech Ltd’s EPS estimate?

Rossari Biotech Ltd’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Rossari Biotech Ltd have?

Rossari Biotech Ltd has 55,383,366 shares outstanding.

What happened to Rossari Biotech Ltd’s price movement after its last earnings report?

Rossari Biotech Ltd reported an EPS of ₹5.9 in its last earnings report, missing expectations of ₹6.2. Following the earnings report the stock price went up 2.125%.

Which hedge fund is a major shareholder of Rossari Biotech Ltd?

Currently, no hedge funds are holding shares in IN:ROSSARI

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Rossari Biotech Ltd

Rossari Biotech Limited engages in manufacture and sale of specialty chemicals in India and internationally. It offers soap and detergents; inks, paints, and coatings; ceramics and tiles; pulp and papers; cement; and water treatment solutions. The company also provides textile specialty chemicals, such as cotton, polyester, acrylic, wool, silk, nylon, functional finishes, denim, and sustainable solutions; and pet grooming products, which include natural pet shampoos, powders, deodorants, sprays, creams, and floor washing liquids under the Lozalo, Hunger Fills, and Sniffy brand names. In addition, it provides poultry nutrition products comprising vitamin-mineral formulations, toxin binders, individual and cocktail enzymes, liquid nutraceuticals, and supplements or herbal preparations. The company was formerly known as Rossari Labtech and changed its name to Rossari Biotech Limited in December 2003. Rossari Biotech Limited was founded in 2003 and is based in Mumbai, India.